Accumulating evidence implicates heterogeneity within cancer cell populations in the response
to stressful exposures, including drug treatments. While modeling the acute response to …

Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …

To understand the role of human epidermal growth factor receptor (hEGFR) kinase domain
mutations in lung tumorigenesis and response to EGFR-targeted therapies, we generated …

Thalidomide-like drugs such as lenalidomide are clinically important treatments for multiple
myeloma and show promise for other B cell malignancies. The biochemical mechanisms …

Germline mutation in serine/threonine kinase 11 (STK11, also called LKB1) results in Peutz–Jeghers
syndrome, characterized by intestinal hamartomas and increased incidence of …

Purpose: HER2 (or ERBB2) aberrations, including both amplification and mutations, have
been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas. …

Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR)
are initially responsive to small molecule tyrosine kinase inhibitors (TKIs), but the efficacy of …

Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the
p110-α catalytic subunit (encoded by PIK3CA) 1 . They are most frequently observed in two …

Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1):
programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to …

The success in lung cancer therapy with programmed death (PD)-1 blockade suggests that
immune escape mechanisms contribute to lung tumor pathogenesis. We identified a …